公开(公告)号：US20150320837A1

公开(公告)日：2015-11-12

申请号：US14652011

申请日：2013-12-12

Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY

Inventor： Daniel G. Anderson ,  Hung-Chieh Chou ,  Matthew J. Webber ,  Benjamin C. Tang ,  Yair Levi ,  Yunlong Zhang ,  Rosemary Lynn Kanasty ,  Arturo Jose Vegas ,  Robert A. Langer

IPC: A61K38/28 ,  G01N33/66 ,  G01N33/74 ,  A61K47/48

CPC classification number: A61K38/28 ,  A61K47/54 ,  A61K47/542 ,  A61K47/543 ,  A61K47/549 ,  A61K47/554 ,  G01N33/66 ,  G01N33/74 ,  G01N2333/62

Abstract: Compounds, compositions, and methods for “smart” delivery of a therapeutic, prophylactic or diagnostic agent, such as glucose-mediated delivery of insulin through glucose-sensing insulin derivatives, are provided. The insulin derivatives bind serum albumin or agglomerate in vivo. The insulin derivatives effectively dissociate to release insulin in a hyperglycemic condition, where the complexation of glucose to a glucose-sensing element alters properties of the insulin derivative leading to the dissociation. The compounds, compositions, and methods provide a delivery strategy for both self-regulated and long-term diabetes management.

Abstract translation: 提供了通过葡萄糖感测胰岛素衍生物“治疗性”，“预防性”或“诊断”（例如葡萄糖介导的胰岛素递送）的“智能”递送的化合物，组合物和方法。 胰岛素衍生物在体内结合血清白蛋白或附聚物。 胰岛素衍生物有效解离以在高血糖状态释放胰岛素，其中葡萄糖与葡萄糖感测元件的络合改变导致胰岛素衍生物的分解导致解离。 化合物，组合物和方法提供了自我调节和长期糖尿病管理的递送策略。

公开(公告)号：US09867869B2

公开(公告)日：2018-01-16

申请号：US14652011

申请日：2013-12-12

Applicant: Massachusetts Institute of Technology ,  The Children's Medical Center Corporation

Inventor： Daniel G. Anderson ,  Hung-Chieh Chou ,  Michael J. Webber ,  Benjamin C. Tang ,  Yair Levi ,  Yunlong Zhang ,  Rosemary Lynn Kanasty ,  Arturo Jose Vegas ,  Robert S. Langer

IPC: A61K38/28 ,  A61K47/48 ,  G01N33/66 ,  G01N33/74

CPC classification number: A61K38/28 ,  A61K47/54 ,  A61K47/542 ,  A61K47/543 ,  A61K47/549 ,  A61K47/554 ,  G01N33/66 ,  G01N33/74 ,  G01N2333/62

Abstract: Compounds, compositions, and methods for “smart” delivery of a therapeutic, prophylactic or diagnostic agent, such as glucose-mediated delivery of insulin through glucose-sensing insulin derivatives, are provided. The insulin derivatives bind serum albumin or agglomerate in vivo. The insulin derivatives effectively dissociate to release insulin in a hyperglycemic condition, where the complexation of glucose to a glucose-sensing element alters properties of the insulin derivative leading to the dissociation. The compounds, compositions, and methods provide a delivery strategy for both self-regulated and long-term diabetes management.

公开(公告)号：US20140220346A1

公开(公告)日：2014-08-07

申请号：US14097212

申请日：2013-12-04

Applicant: Memorial Sloan-Kettering Cancer Center ,  Massachusetts Institute of Technology

Inventor： Daniel A. Heller ,  Jasmine Wallas ,  Yair Levi ,  George W. Pratt ,  Daniel G. Anderson ,  Robert Langer

IPC: A61K47/48 ,  A61K49/00

CPC classification number: A61K49/0073 ,  A61K49/0032 ,  A61K49/0052 ,  A61K49/0054 ,  A61K51/065 ,  A61K51/1213 ,  Y10T428/2982

Abstract: In certain embodiments, a nano-sized vehicle (e.g., a nanogel comprising nanoparticles) is provided herein for drug delivery with tunable biodistribution, low toxicity, and degradability, and with demonstrated targeting to bone. The composition is useful, for example, in the treatment of bone disease, particularly bone metastases from cancers such as breast, prostate, or lung cancer.

Abstract translation: 在某些实施方案中，本文提供了纳米级载体（例如，包含纳米颗粒的纳米凝胶）用于具有可调节的生物分布，低毒性和降解性的药物递送，并且已经证实靶向骨。 该组合物可用于例如治疗骨疾病，特别是来自癌症如乳腺癌，前列腺癌或肺癌的骨转移瘤。